12967_2019_2087_MOESM9_ESM.pdf (489.29 kB)
MOESM9 of Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy
journal contribution
posted on 2019-10-10, 08:55 authored by Xiaohong Han, Ying Han, Qiaoyun Tan, Yu Huang, Jianliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, Yan Song, Jinping Pi, Lijie Zuo, Jiarui Yao, Di Wu, Zhishang Zhang, Yuankai ShiAdditional file 9: Fifure S4. Landscape of potentially clinically actionable variants in plasma of LUAD. (A)Number of individuals for targeting therapy during chemotherapy and mutated frequency of genes. Pre (goldenrod1): patients have potential drug targets only in pre chemotherapy; Pre & Post (grey): patients have potential drug targets in pre and post chemotherapy; Post (indianred): patients have potential drug targets only in post chemotherapy). Each bar represented a category. (B) Number of individuals for targeting therapy, each bar represented a gene. (C) Variants in genes (rows) that may predict sensitivity to ERK-Signalling, PI3K/MTOR inhibitor. Vertical columns correspond to plasma samples.